Quote from: Amy1988 on June 11, 2014, 12:06:25 PM
I can't seem to find answers to some questions about transdermal estrogen. Maybe someone here knows. My question is does transdermal E go through the liver at all and if so does it stimulate clotting chemicals? If there is a first pass then what is the second pass?
only estrogen PLUS progesterone rises the risk of thrombosis (formation of clots), estrogen alone by any way does not increase your risk of thrombosis
Fertil Steril. 2010 Mar 1;93(4):1267-72. doi: 10.1016/j.fertnstert.2008.12.017. Epub 2009 Feb 6.
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
Ott J1, Kaufmann U, Bentz EK, Huber JC, Tempfer CB.
Author information
Abstract
OBJECTIVE:
To evaluate the incidence of venous thromboembolism (VTE) in transsexual patients and the value of screening for thrombophilia in this population.
DESIGN:
Retrospective cohort study.
SETTING:
Academic research institution.
PATIENT(S):
Two hundred fifty-one transsexuals (162 male-to-female [MtF] and 89 female-to-male [FtM] transsexuals).
INTERVENTION(S):
Screening for activated protein C (aPC) resistance, antithrombin III, free protein S antigen, and protein C deficiency.
MAIN OUTCOME MEASURE(S):
Incidence of thrombophilic defects and VTE during cross-sex hormone therapy.
RESULT(S):
Activated protein C resistance was detected in 18/251 patients (7.2%), and protein C deficiency was detected in one patient (0.4%). None of the patients developed VTE under cross-sex hormone therapy during a mean of 64.2 +/- 38.0 months. There was no difference in the incidence of thrombophilia comparing MtF and FtM transsexuals (8.0% [13/162] vs. 5.6% [5/89], respectively).
CONCLUSION(S):
VTE during cross-sex hormone therapy is rare. General screening for thrombophilic defects in transsexual patients is not recommended. Cross-sex hormone therapy is feasible in MtF as well as in FtM patients with aPC resistance.